Haemonetics Corp

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Haemonetics Corp
TickerHAE
CIK #0000313143
CUSIP405024100
SectorLife Sciences
IndustrySurgical & Medical Instruments & Apparatus
Phone7818487100
Address400 Wood Rd
Braintree, MA 02184
Source [EDGAR]
Market Cap, 13F ($)
Business

Haemonetics is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions to customers to help improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets including blood and plasma component collection, the surgical suite, and hospital transfusion services. When used in this report, the terms "we," "us," "our" and "the Company" mean Haemonetics.

Blood is essential to a modern healthcare system. Blood and its components (plasma, platelets and red cells) have many vital and frequently life-saving clinical applications. Plasma is used for patients with major blood loss and is manufactured into biopharmaceuticals to treat a variety of illnesses, including immune diseases and coagulation disorders. Red cells treat trauma patients or patients undergoing surgery with high blood loss, such as open heart surgery or organ transplant. Platelets have many uses in patient care, including supporting cancer patients undergoing chemotherapy.

Haemonetics develops and markets a wide range of devices and solutions to serve our customers. Our Plasma business unit provides plasma collection devices and disposables and plasma donor management software that enable the collection of plasma used by biopharmaceutical companies to make life saving pharmaceuticals. Our Blood Center business unit offers blood collection and processing devices and disposables for red cells, platelets and whole blood as well as related donor management

CIK Filing 2011 - 2023
[0000313143] 10-K
[0000313143] 10-Q
[0000313143] 3
[0000313143] 4
[0000313143] 5
[0000313143] 8-K
[0000313143] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Capital Research Global Investors Haemonetics Corp [2022-04-08] 10.7
Wellington Management Group LLP Haemonetics Corp [2022-02-04] 0.96
Capital Research Global Investors Haemonetics Corp [2020-02-14] 5.3
Neuberger Berman Group LLC Haemonetics Corp [2020-02-14] 5.15
Black Creek Investment Management Inc Haemonetics Corp [2017-02-15] 2.17
Wellington Management Group LLP Haemonetics Corp [2017-02-09] 6.62
Black Creek Investment Management Inc Haemonetics Corp [2016-02-16] 5.1
Price T Rowe Associates Inc /MD/ Haemonetics Corp [2016-02-12] 5.2
Vanguard Group Inc Haemonetics Corp [2012-02-08] 5.5
Form 3/4/5 Filer 2011 - 2023
Haemonetics Corp
Strong Stewart W
Miller Laurie A.
Lingamneni Anila
Simon, Christopher
Basil Michelle L
Llorens Josep
DArecca James
Maunsell Farris Maryanne
Galvin Roy
Kroll Mark W
Pomeroy Claire
Zane Ellen M
Johnson Lloyd Emerson
Dockendorff Charles J
Coyle Michael J
Burzik Catherine M
Abernathy Robert E
Goldstein Dan
Burke William P. Mr.
Nikel Chad M.
Scanlan Jacqueline
Meelia Richard J
Gelbman Ronald G
Bolorforosh Said
Granadillo Pedro P
Ryding Neil Mr.
Foote Susan Bartlett
Merriman Ronald
Jesse Sandra
Fusco David
Selman Byron
Lindop Christopher J
Hanlon Susan M
White Jonathan
Davies Kent J
Burns Brian R
Concannon Brian
Allen Peter M
Helsel Dave
McDaniel Kathleen
Best Lawrence C
Kelly Michael P
Black Paul
Nighan Warren JR
Forish Joseph J
Gordon Mikael
Shares Owned of Total
Firm Period DFND Voting Shares
Capital Research Global Investors [2023-03-31] DFND 6,653,742.0 6,653,742.0
BlackRock Inc. [2023-03-31] SOLE 5,694,571.0 5,775,277.0
Vanguard Group Inc [2023-03-31] SOLE 0.0 5,186,228.0
Neuberger Berman Group LLC [2023-03-31] DFND 3,499,521.0 3,636,395.0
Wellington Management Group LLP [2023-03-31] DFND 0.0 3,578,714.0
FMR LLC [2023-03-31] DFND 1,863,018.0 1,864,946.0
State Street Corp [2023-03-31] DFND 1,613,730.0 1,734,780.0
Franklin Resources Inc [2023-03-31] DFND 1,413,455.0 1,415,495.0
Fisher Asset Management LLC [2023-03-31] DFND 436,589.0 1,043,210.0
Schroder Investment Management Group [2023-03-31] SOLE 945,624.0 945,624.0
Geode Capital Management LLC [2023-03-31] DFND 935,134.0 943,722.0
Royce & Associates LP [2023-03-31] SOLE 843,754.0 843,754.0
Arrowstreet Capital Limited Partnership [2023-03-31] DFND 652,013.0 661,048.0
Boston Trust Walden Corp [2023-03-31] DFND 536,423.0 648,907.0
Northern Trust Corp [2023-03-31] DFND 39,342.0 648,295.0
Dimensional Fund Advisors LP [2023-03-31] SOLE 590,365.0 640,011.0
Boston Partners [2023-03-31] DFND 587,819.0 616,188.0
Bank of New York Mellon Corp [2023-03-31] DFND 506,574.0 521,813.0
Charles Schwab Investment Management Inc [2023-03-31] SOLE 486,297.0 486,297.0
Ameriprise Financial Inc [2023-03-31] DFND 0.0 460,242.0
Price T Rowe Associates Inc /MD/ [2023-03-31] SOLE 125,018.0 459,218.0
Envestnet Asset Management Inc [2023-03-31] SOLE 406,531.0 406,531.0
Westfield Capital Management Co LP [2023-03-31] SOLE 306,486.0 373,456.0
Invesco Ltd. [2023-03-31] DFND 0.0 372,748.0
Heartland Advisors Inc [2023-03-31] DFND 328,491.0 328,491.0
Aristotle Capital Boston LLC [2023-03-31] SOLE 265,174.0 305,784.0
Allspring Global Investments Holdings, LLC [2023-03-31] DFND 99,190.0 302,179.0
Deutsche Bank AG [2023-03-31] DFND 191,311.0 295,794.0
Two Sigma Advisers LP [2023-03-31] SOLE 246,155.0 281,955.0
Morgan Stanley [2023-03-31] DFND 182,430.0 245,598.0
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com